Date:4/29/2009

EBITDA per adjusted prescription $2.86 $2.96 ===== ===== (1) Includes majority-owned Europa Apotheek Venlo's operating results commencing on the April 28, 2008 acquisition date. (2) Includes a $9.8 million charge for the ineffective portion of the forward-starting interest rate swap agreements associated with the March 2008 issuance of senior notes. (3) Adjusted prescription volume equals substantially all mail-order prescriptions multiplied by three, plus retail prescriptions. These mail-order prescriptions are multiplied by three to adjust for the fact that they include approximately three times the amount of product days supplied compared with retail prescriptions. Medco Health Solutions, Inc. Accredo Health Group (Specialty Pharmacy) Segment Results (Unaudited) (In millions) Table 7. Quarter Ended Quarter Ended March 28, Increase March 29, 2009 (Decrease) 2008 ---------- ---------- ---------- Specialty Pharmacy: ------------------- Product net revenues $2,263.9 $389.4 20.8% $1,874.5 Service revenues 22.4 7.3 48.3% 15.1 ---- --- ---- ---- Total net revenues 2,286.3 396.7 21.0% 1,889.6 Total cost of revenues 2,108.8 364.3 20.9% 1,744.5 Selling, general and administrative expenses 74.8 4.4 6.3% 70.4 Amortization of intangibles 11.4 0.4 3.6% 11.0
'/>"/>

SOURCE Medco Health Solutions, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Related biology technology :

1. Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value
2. Medco to Present at the Deutsche Bank 33rd Annual Health Care Conference
3. Medco Issues $1.5 Billion of Senior Notes
4. Addressing the Pharmacist Shortage: Medco Labor Coalition(TM) Launches National Scholarship Program to Support the Development of the Next Generation of Pharmacists
5. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
6. Medco to Webcast Annual Analyst Day Conference
7. Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion
8. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
9. Fat droplet nanoparticle delivers tumor suppressor gene to tumor and metastatic cells
10. Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
11. ICON Delivers New Electronic Solution to Expedite Clinical Trial Adjudication